Under-eye medicine has a nasty habit of outrunning the evidence, which makes LRM's decision to put injectable rhPDGF-BB through more formal study worth watching. Lynch Regenerative Medicine has announced two FDA-accepted INDs for investigator-initiated clinical trials: one examining what the material does inside facial skin, the other testing it for infraorbital hollowing. This is not an approval victory, and nobody should dress it up as one. It is permission to conduct defined clinical research on an injectable use that remains investigational.
Two Trials, Two Very Different Questions
The Michael Somenek-led study is the science-heavy piece. It will enroll 12 participants and use skin biopsies taken at 7 days, 14 days, 28 days, or eight weeks after injection. Researchers plan to assess gene and protein-expression changes, including the skin's natural production of collagen, elastin, and other extracellular-matrix components. Completion is anticipated in the second quarter of 2027.
Twelve people is a tiny dataset. No point pretending otherwise. But it is not trying to settle commercial demand or prove a broad cosmetic claim; it is designed to investigate biological activity and mechanism. For a regenerative-medicine platform, that distinction matters. If the readout shows a coherent cellular signal, it could help LRM build a more credible clinical rationale for future work. If it does not, the marketing story gets a lot harder to sustain.
The Under-Eye Study Carries the Practical Test
Sarah Allen's investigator-initiated trial goes after infraorbital hollowing, a familiar and stubborn aesthetic complaint. The 30-participant study will evaluate safety and efficacy of under-eye rhPDGF-BB injections, with outcomes assessed 12 weeks after treatment. The stated targets include skin quality, tear-trough appearance, dark shadows, and under-eye thickness, smoothness, and brightness. That study is expected to finish in the third quarter of 2027.
Those are meaningful endpoints to patients, but this is where discipline matters most. The under-eye area is unforgiving. A treatment can sound elegant on paper and still run into real-world issues around consistency, durability, technique, tolerability, or whether the visible change is strong enough to matter. Thirty participants can generate a useful early signal, not a final verdict. Anyone treating this announcement as proof that injectable pure PDGF has solved tear troughs is getting ahead of the facts.
FDA IND authorization allows clinical investigation; it does not mean the injectable applications have been approved for aesthetic use.
Why the Existing Platform Still Matters
LRM is not approaching PDGF as a brand-new molecule dreamed up for a social-media trend. The company says rhPDGF-BB has a long clinical record in other medical fields, and its therapeutic portfolio includes Regranex Gel, an FDA-approved prescription biologic for chronic wounds, and GEM 21S, an FDA-approved periodontal regeneration product. That background does not automatically transfer to facial injections, of course. Different anatomy, different expectations, different risk profile. Still, prior experience with the growth factor gives the research program more footing than a typical aesthetics launch built mainly on before-and-after enthusiasm.
There is also a separate LRM Phase IIb multicenter trial already evaluating injectable rhPDGF-BB for infraorbital hollowing. These two new efforts are complementary rather than replacements: one potentially helps explain the biology, while the other adds another clinical lens on the under-eye use case. That is a sensible research stack, even if it leaves plenty unanswered.
Investors Should Separate the Cosmetic Product From the Injection
LRM already markets ariessence pure PDGF+, a topical cosmetic product containing rhPDGF-BB and hyaluronic acid. The company says it was introduced just over two years ago and has been used post-procedure by hundreds of thousands of people. Fine, but topical cosmetic use and an investigational injectable application are not interchangeable. They should not be blended into one giant efficacy claim. Different route, different regulatory posture, different clinical burden.
For sector watchers, the next real checkpoints are straightforward: whether the small studies complete on the stated 2027 timetable, what the safety findings show, and whether objective results line up with the desired aesthetic outcomes. LRM has put more research on the board. Good. The hard part, as usual, is turning that research into reproducible evidence without letting the promise of regenerative aesthetics outrun the data.